The cell therapy market is valued at 15 billion dollars and is set to double in value by 2030. Cell therapy has been instrumental in the development of treatments like CAR-T therapy, which uses the body’s own T cells to fight cancer. The opportunity within cell therapy is significant, targeting common diseases that afflict millions […]
In July of 2022, AllCells was acquired by Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists™. By combining over 30 years of cell and gene therapy (CGT) expertise, our clients now have access to an enhanced donor collection network, the world’s largest biospecimen inventory, and a wide range of multi-omic biomarker services. AllCells’ proven […]
Unlike classical therapeutics (i.e., monoclonal antibodies), the raw starting materials for cell and gene therapies (CGTs) are derived from patient or donor cells. As such, these sources are not mass-produced and are inherently sensitive to supply chain complications. Access to these essential starting materials hinges on donor access, collection facility capacity, processing expertise, distribution networks, […]
A decade ago, the emergence of new immunotherapies in the cell and gene therapy (CGT) space opened up new avenues to treat disease, sparking excitement across the industry. However, the path to commercialization has been a steep learning curve for both companies and regulatory agencies given the uncharted waters of these new modalities. Now that […]
By 2026, commercial chimeric antigen receptor (CAR)-T cell therapies are on track to make up the largest share of oncology drug sales for pediatric and young adult patients1. This is impressive given that the first CAR-T therapies only gained US Food and Drug Administration (FDA) approval in 2017 and demonstrates the power of these new […]
Mobilized peripheral blood has now surpassed bone marrow as the preferred source of CD34+ hematopoietic stem and progenitor cells (HSPCs) for allogeneic hematologic transplantation and translational medicines because both the mobilization and collection procedures are far less invasive for donors with fewer side effects. Another benefit is that significantly more CD34+ cells can be isolated […]
Hematopoietic stem cells (HSCs) have immense therapeutic potential because of their ability for both self-renewal and multi-lineage differentiation to maintain hematopoietic homeostasis. This rare population of cells are characterized by the presence of the cell surface marker CD34, which is useful for their identification and isolation from the bone marrow and peripheral blood. In the […]
After a decade of innovation, chimeric antigen receptor (CAR)-T cell therapy remains at the forefront of the cell and gene therapy space, continuing to forge new ground to treat previously intractable cancers and diseases (Figure 1). Since 2017, six CAR-T cell therapies have been approved by the Food and Drug Administration (FDA) and all are […]
Cell and gene therapies represent an expanding category of transformative medicines with the potential to change the way we treat human diseases. Broadly, these novel therapies include both in vivo and ex vivo strategies to modify target cells. Ex vivo therapies that involve isolating cells from a patient (autologous) or a donor (allogeneic) and modifying […]
Growth in the Regenerative Medicine Field The regenerative medicine sector is on track for another watershed year where clinical progress, continued growth, and segmentation into new disease areas affecting larger patient populations is anticipated. With over 2,600 active clinical trials in 2021, the clinical pipeline is maturing at a rapid pace. Forty three percent of […]
